These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28140693)

  • 21. In vitro activities of tedizolid compared with other antibiotics against Gram-positive pathogens associated with hospital-acquired pneumonia, skin and soft tissue infection and bloodstream infection collected from 26 hospitals in China.
    Li S; Guo Y; Zhao C; Chen H; Hu B; Chu Y; Zhang Z; Hu Y; Liu Z; Du Y; Gui Q; Ji P; Zeng J; Cao B; Fu Q; Zhang R; Wang Z; Zhuo C; Feng X; Jia W; Jin Y; Xu X; Liao K; Ni Y; Yu Y; Xu X; Hu Z; Lei JE; Yang Q; Wang H
    J Med Microbiol; 2016 Oct; 65(10):1215-1224. PubMed ID: 27599998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Response of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials.
    Sandison T; De Anda C; Fang E; Das AF; Prokocimer P
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tedizolid population pharmacokinetics, exposure response, and target attainment.
    Flanagan S; Passarell J; Lu Q; Fiedler-Kelly J; Ludwig E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6462-70. PubMed ID: 25136028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.
    Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics, Safety and Tolerability of Single Oral or Intravenous Administration of 200 mg Tedizolid Phosphate in Adolescents.
    Bradley JS; Flanagan SD; Arrieta AC; Jacobs R; Capparelli E; Prokocimer P
    Pediatr Infect Dis J; 2016 Jun; 35(6):628-33. PubMed ID: 26910588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Translational Pharmacokinetic/Pharmacodynamic Infection Models To Understand the Impact of Neutropenia on the Efficacy of Tedizolid Phosphate.
    Xiao J; Gill C; Liang L; Liu J; Wu J; Feng HP; Flanagan S; Tan C; Flattery A
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tedizolid: a new oxazolidinone antimicrobial.
    Kisgen JJ; Mansour H; Unger NR; Childs LM
    Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate After Single-dose Administration in Healthy Korean Male Subjects.
    Kim Y; Kim A; Lee S; Choi SH; Lee DY; Song JS; Lee H; Jang IJ; Yu KS
    Clin Ther; 2017 Sep; 39(9):1849-1857. PubMed ID: 28865799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary.
    Das D; Tulkens PM; Mehra P; Fang E; Prokocimer P
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S51-7. PubMed ID: 24343833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections.
    Delpech P; ALeryan M; Jones B; Gemmell C; Lang S
    Diagn Microbiol Infect Dis; 2018 May; 91(1):93-97. PubMed ID: 29452993
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections.
    Hardalo C; Lodise TP; Bidell M; Flanagan S; De Anda C; Anuskiewicz S; Prokocimer P
    Expert Opin Drug Saf; 2018 Apr; 17(4):359-367. PubMed ID: 29528251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary.
    O'Riordan W; Green S; Mehra P; De Anda C; Fang E; Prokocimer P
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S43-50. PubMed ID: 24343832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tedizolid for the management of human infections: in vitro characteristics.
    Locke JB; Zurenko GE; Shaw KJ; Bartizal K
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S35-42. PubMed ID: 24343830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials.
    Corey R; Moran G; Goering R; Bensaci M; Sandison T; De Anda C; Prokocimer P
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):277-286. PubMed ID: 30940414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, Safety, and Tolerability of Tedizolid Phosphate in Elderly Subjects.
    Flanagan SD; Minassian SL; Prokocimer P
    Clin Pharmacol Drug Dev; 2018 Sep; 7(7):788-794. PubMed ID: 29319932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An evaluation of tedizolid for the treatment of MRSA infections.
    Hall RG; Smith WJ; Putnam WC; Pass SE
    Expert Opin Pharmacother; 2018 Sep; 19(13):1489-1494. PubMed ID: 30200779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the haematological profile of 21 days of tedizolid in healthy subjects.
    Lodise TP; Bidell MR; Flanagan SD; Zasowski EJ; Minassian SL; Prokocimer P
    J Antimicrob Chemother; 2016 Sep; 71(9):2553-8. PubMed ID: 27317442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.
    Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections.
    Russo A; Concia E; Cristini F; De Rosa FG; Esposito S; Menichetti F; Petrosillo N; Tumbarello M; Venditti M; Viale P; Viscoli C; Bassetti M
    Clin Microbiol Infect; 2016 Apr; 22 Suppl 2():S27-36. PubMed ID: 27125562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid.
    Flanagan S; Fang E; Muñoz KA; Minassian SL; Prokocimer PG
    Pharmacotherapy; 2014 Sep; 34(9):891-900. PubMed ID: 24989138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.